

Markus MÃ¼schen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5298370/publications.pdf>

Version: 2024-02-01

178
papers

6,031
citations

76322

40
h-index

79691

73
g-index

181
all docs

181
docs citations

181
times ranked

10037
citing authors

#	ARTICLE	IF	CITATIONS
1	CCND3 is indispensable for the maintenance of B-cell acute lymphoblastic leukemia. <i>Oncogenesis</i> , 2022, 11, 1.	4.9	7
2	An instructive role for Interleukin-7 receptor $\hat{I}\pm$ in the development of human B-cell precursor leukemia. <i>Nature Communications</i> , 2022, 13, 659.	12.8	12
3	SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. <i>Cellular Signalling</i> , 2022, 94, 110331.	3.6	10
4	Metabolic Gatekeepers of Pathological B Cell Activation. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 323-349.	22.4	10
5	PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	10
6	R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. <i>Molecular Cell</i> , 2021, 81, 922-939.e9.	9.7	157
7	Topography of transcriptionally active chromatin in glioblastoma. <i>Science Advances</i> , 2021, 7, .	10.3	19
8	Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. <i>Molecular Cell</i> , 2021, 81, 2094-2111.e9.	9.7	17
9	Metabolic determinants of B-cell selection. <i>Biochemical Society Transactions</i> , 2021, 49, 1467-1478.	3.4	0
10	Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 3526.	12.8	34
11	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1820-1835.	4.1	9
12	High-resolution characterization of gene function using single-cell CRISPR tiling screen. <i>Nature Communications</i> , 2021, 12, 4063.	12.8	23
13	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. <i>Nature Communications</i> , 2021, 12, 5337.	12.8	14
14	Beta-Catenin Forms Repressive Complexes with Ikaros1 and Ikaros3 to Orchestrate Tumor-Suppression in B-Cell Malignancies. <i>Blood</i> , 2021, 138, 29-29.	1.4	0
15	Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 616-616.	1.4	1
16	Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation. <i>Blood</i> , 2021, 138, 868-868.	1.4	0
17	Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation. <i>Blood</i> , 2021, 138, 792-792.	1.4	0
18	Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. <i>Nature Communications</i> , 2021, 12, 6522.	12.8	19

#	ARTICLE	IF	CITATIONS
19	Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies. <i>Blood</i> , 2021, 138, 355-355.	1.4	0
20	CRISPR/Cas9-mediated gene deletion efficiently retards the progression of Philadelphia-positive acute lymphoblastic leukemia in a p210 BCR-ABL1T315I mutation mouse model. <i>Haematologica</i> , 2020, 105, e232-e236.	3.5	4
21	Signalling input from divergent pathways subverts B ¹ cell transformation. <i>Nature</i> , 2020, 583, 845-851.	27.8	37
22	<i>MEF2D</i> Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL. <i>Blood Cancer Discovery</i> , 2020, 1, 18-20.	5.0	3
23	Core transcriptional regulatory circuitries in cancer. <i>Oncogene</i> , 2020, 39, 6633-6646.	5.9	41
24	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B ¹ cells. <i>Nature</i> , 2020, 588, 491-497.	27.8	57
25	Coactivation of NF- κ B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. <i>Blood</i> , 2020, 135, 108-120.	1.4	14
26	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. <i>Cancer Cell</i> , 2020, 38, 79-96.e11.	16.8	389
27	Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Nature Communications</i> , 2020, 11, 3194.	12.8	13
28	Integrin α 6 mediates the drug resistance of acute lymphoblastic B-cell leukemia. <i>Blood</i> , 2020, 136, 210-223.	1.4	31
29	IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. <i>Blood</i> , 2020, 136, 1520-1534.	1.4	28
30	Rationale for targeting BCL6 in <i>MLL</i> -rearranged acute lymphoblastic leukemia. <i>Genes and Development</i> , 2019, 33, 1265-1279.	5.9	17
31	Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 1257-1268.	1.4	30
32	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	67
33	Chemical choreography of germinal center B-cell migration. <i>Cell Research</i> , 2019, 29, 514-515.	12.0	0
34	Metabolic gatekeepers to safeguard against autoimmunity and oncogenic B cell transformation. <i>Nature Reviews Immunology</i> , 2019, 19, 337-348.	22.7	37
35	Histone H3 trimethylation at lysine 36 guides m6A RNA modification co-transcriptionally. <i>Nature</i> , 2019, 567, 414-419.	27.8	452
36	Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID. <i>Nature Communications</i> , 2019, 10, 5563.	12.8	21

#	ARTICLE	IF	CITATIONS
37	Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. <i>Blood</i> , 2019, 133, 306-318.	1.4	26
38	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. <i>Blood</i> , 2019, 134, 393-393.	1.4	0
39	Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL. <i>Blood</i> , 2019, 134, 3785-3785.	1.4	0
40	Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation. <i>Blood</i> , 2019, 134, 3944-3944.	1.4	0
41	Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies. <i>Blood</i> , 2019, 134, 295-295.	1.4	0
42	Autonomous Ca ²⁺ Oscillations Reflect Oncogenic Signaling in B-ALL Cells. <i>Blood</i> , 2019, 134, 1253-1253.	1.4	1
43	Ifitm3 Is Essential for PI(3,4,5)P ₃ -Dependent B-Cell Activation and Leukemogenesis. <i>Blood</i> , 2019, 134, 2782-2782.	1.4	1
44	Identification of ZNF217 As an Essential Oncogenic Gene in B-Cell Acute Lymphoblastic Leukemia By CRISPR/Cas9-Based Library Screening. <i>Blood</i> , 2019, 134, 1465-1465.	1.4	0
45	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. <i>Blood</i> , 2019, 134, 1239-1239.	1.4	0
46	Paraoxonase 2 Enables Initiation of B-ALL By Subverting Metabolic Gatekeeper Functions. <i>Blood</i> , 2019, 134, 746-746.	1.4	1
47	Lgr5 Functions As a Critical Negative Regulator of Wnt/ β -Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation. <i>Blood</i> , 2019, 134, 748-748.	1.4	0
48	Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2836-2841.	7.1	44
49	Loss of Pax5 Exploits Sca1-BCR-ABLp190 Susceptibility to Confer the Metabolic Shift Essential for pB-ALL. <i>Cancer Research</i> , 2018, 78, 2669-2679.	0.9	37
50	Autoimmunity checkpoints as therapeutic targets in B cell malignancies. <i>Nature Reviews Cancer</i> , 2018, 18, 103-116.	28.4	38
51	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. <i>Cell</i> , 2018, 173, 470-484.e18.	28.9	89
52	Portending death in germinal centers “when B cells know their time is up. <i>Cell Research</i> , 2018, 28, 5-6.	12.0	1
53	CAMKs support development of acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2018, 11, 30.	17.0	26
54	Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. <i>Cell Reports</i> , 2018, 23, 3127-3136.	6.4	68

#	ARTICLE	IF	CITATIONS
55	Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies. <i>Blood</i> , 2018, 132, 3922-3922.	1.4	2
56	Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies. <i>Blood</i> , 2018, 132, 547-547.	1.4	3
57	Divergent Evolutionary Trajectories of Erk- and Stat5-Activating Lesions in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 568-568.	1.4	0
58	IFITM3-Mediated Regulation of Cell Membrane Dynamics Is Essential for Malignant B-Cell Transformation. <i>Blood</i> , 2018, 132, 552-552.	1.4	2
59	Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. <i>Blood</i> , 2018, 132, 1411-1411.	1.4	0
60	Autoimmunity Checkpoints As Therapeutic Targets in B-Cell Malignancies. <i>Blood</i> , 2018, 132, 1587-1587.	1.4	0
61	Pre-BCR Surrogate Light Chain Components VPREB1 and IGLL1 Function As Pre-BCR-Independent Tumor Suppressors in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 570-570.	1.4	0
62	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. <i>Molecular Systems Biology</i> , 2017, 13, 914.	7.2	73
63	Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1+ pre-B ALL. <i>Journal of Experimental Medicine</i> , 2017, 214, 793-814.	8.5	34
64	Metabolic gatekeeper function of B-lymphoid transcription factors. <i>Nature</i> , 2017, 542, 479-483.	27.8	175
65	Lineage-Specific Genes Are Prominent DNA Damage Hotspots during Leukemic Transformation of B Cell Precursors. <i>Cell Reports</i> , 2017, 18, 1687-1698.	6.4	15
66	Infection Exposure Promotes ETV6-RUNX1 Precursor B-cell Leukemia via Impaired H3K4 Demethylases. <i>Cancer Research</i> , 2017, 77, 4365-4377.	0.9	76
67	mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1942-1953.	4.1	10
68	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. <i>Nature Immunology</i> , 2017, 18, 694-704.	14.5	67
69	BCL6 promotes glioma and serves as a therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3981-3986.	7.1	58
70	Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. <i>Blood</i> , 2017, 129, 1155-1165.	1.4	64
71	Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , 2017, 8, 978.	12.8	58
72	Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , 2017, 19, 750-761.	5.3	20

#	ARTICLE	IF	CITATIONS
73	Circadian clock cryptochrome proteins regulate autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12548-12553.	7.1	84
74	B-cell identity as a metabolic barrier against malignant transformation. Experimental Hematology, 2017, 53, 1-6.	0.4	11
75	Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. Journal of Clinical Investigation, 2017, 127, 2392-2406.	8.2	64
76	Autoimmunity Checkpoints As Therapeutic Targets in B- and T-Cell Malignancies. Blood, 2017, 130, 718-718.	1.4	0
77	PON2 Exemplifies a Unique Dependency of B Cell Lineage ALL Cells on Detoxifying Lactonases. Blood, 2017, 130, 882-882.	1.4	0
78	Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 174, 425-436.	2.5	27
79	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227
80	Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood, 2016, 127, 2131-2143.	1.4	32
81	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature Medicine, 2016, 22, 379-387.	30.7	94
82	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. Blood, 2016, 128, 2763-2763.	1.4	5
83	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. Blood, 2016, 128, 4088-4088.	1.4	2
84	Inhibition of IRE1 α -driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget, 2016, 7, 18736-18749.	1.8	71
85	Feedback Regulation of STAT5 Is Critical to Balance MYC and BCL6-Dependent Transcriptional Programs That Regulate Cell Size and Glucose Metabolism. Blood, 2016, 128, 4069-4069.	1.4	1
86	IFITM3 Is a Central Regulator of Lipid Raft Signaling and Essential for CD19 Surface Expression and PI3K Signaling in Human B Cell Malignancies. Blood, 2016, 128, 2738-2738.	1.4	0
87	Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments. Blood, 2016, 128, 4077-4077.	1.4	0
88	Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2771-2771.	1.4	0
89	Transcriptional Control of Glucose and Energy Supply Prevents Oncogenic Signaling and B Cell Transformation. Blood, 2016, 128, 437-437.	1.4	0
90	PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia. Blood, 2016, 128, 1056-1056.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 907-907.	1.4	0
92	BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. <i>Blood</i> , 2016, 128, 438-438.	1.4	0
93	MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. <i>Blood</i> , 2015, 126, 2202-2212.	1.4	88
94	Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. <i>Blood</i> , 2015, 126, 1813-1822.	1.4	75
95	Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. <i>Nature Immunology</i> , 2015, 16, 766-774.	14.5	163
96	Infection and the Perils of B-cell Activation. <i>Cancer Discovery</i> , 2015, 5, 1244-1246.	9.4	8
97	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. <i>Cell Reports</i> , 2015, 13, 2715-2727.	6.4	118
98	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 27, 409-425.	16.8	109
99	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 114-128.	16.8	107
100	Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 3688-3693.	1.4	38
101	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , 2015, 521, 357-361.	27.8	127
102	YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. <i>Journal of Hematology and Oncology</i> , 2015, 8, 39.	17.0	32
103	Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2015, 6, 6471.	12.8	41
104	Human Lymphoid Translocation Fragile Zones Are Hypomethylated and Have Accessible Chromatin. <i>Molecular and Cellular Biology</i> , 2015, 35, 1209-1222.	2.3	8
105	Mechanisms of pre-B cell receptor checkpoint control and its oncogenic subversion in acute lymphoblastic leukemia. <i>Immunological Reviews</i> , 2015, 263, 192-209.	6.0	33
106	Circadian Clock Protein CRY Controls B-Cell Intrinsic Tolerance. <i>Blood</i> , 2015, 126, 1029-1029.	1.4	2
107	IFITM3 (CD225) Links the B Cell Antigen CD19 to PI3K-AKT Signaling in Human ALL Cells. <i>Blood</i> , 2015, 126, 1325-1325.	1.4	2
108	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1434-1434.	1.4	6

#	ARTICLE	IF	CITATIONS
109	Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10. <i>Blood</i> , 2015, 126, 2525-2525.	1.4	3
110	Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2529-2529.	1.4	3
111	Infectious origins of childhood leukemia. <i>Oncotarget</i> , 2015, 6, 16798-16799.	1.8	8
112	Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 166-166.	1.4	0
113	Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors. <i>Blood</i> , 2015, 126, 50-50.	1.4	8
114	B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling. <i>Blood</i> , 2015, 126, 1255-1255.	1.4	0
115	Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3716-3716.	1.4	0
116	Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation. <i>Blood</i> , 2015, 126, 1875-1875.	1.4	0
117	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 556-556.	1.4	0
118	PP2A Is Required for B Cell Survival and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 902-902.	1.4	0
119	Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. <i>Current Opinion in Hematology</i> , 2014, 21, 341-349.	2.5	33
120	BACH2â€“BCL6 balance regulates selection at the pre-B cell receptor checkpoint. <i>Trends in Immunology</i> , 2014, 35, 131-137.	6.8	30
121	RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2014, 46, 116-125.	21.4	313
122	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2219-28.	7.1	78
123	Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL. <i>Scientific Reports</i> , 2014, 4, 6565.	3.3	13
124	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. <i>Nature Medicine</i> , 2013, 19, 1014-1022.	30.7	100
125	Brutonâ€™s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1399-1399.	1.4	7
126	BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1456-1456.	1.4	2

#	ARTICLE	IF	CITATIONS
127	Ifitm3 (CD225) Mediates CD19-Dependent Survival and Proliferation During Normal B Cell Development and In Ph+ ALL. Blood, 2013, 122, 2505-2505.	1.4	5
128	Gas7 Induces The Proliferation Of Ph+ ALL Cells and Prevents The Differentiation Of Early B Cell Progenitors Into CD25high Small Pre-B Cells. Blood, 2013, 122, 2506-2506.	1.4	1
129	Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199. Blood, 2013, 122, 3919-3919.	1.4	2
130	Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated "Dual Synthetic Lethality" To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells. Blood, 2013, 122, 810-810.	1.4	2
131	Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia. Blood, 2013, 122, 349-349.	1.4	1
132	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. Blood, 2013, 122, 229-229.	1.4	0
133	Normal ABL1 Is a Tumor Suppressor and Therapeutic Target In BCR-ABL1 "positive Leukemias. Blood, 2013, 122, 1466-1466.	1.4	0
134	Identification Of FOXM1 As Therapeutic Target In BCR-ABL1 Positive Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1250-1250.	1.4	0
135	The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL. Blood, 2013, 122, 836-836.	1.4	0
136	Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. Blood, 2013, 122, 72-72.	1.4	0
137	Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia. Cancer Discovery, 2012, 2, 1004-1023.	9.4	80
138	Targeting the UPR-Transcription Factor XBP1 to Overcome Drug-Resistance in Ph+ ALL. Blood, 2012, 120, 872-872.	1.4	1
139	SOX4 enables Oncogenic Survival Signals in Acute Lymphoblastic Leukemia. Blood, 2012, 120, 863-863.	1.4	0
140	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. Blood, 2012, 120, 1300-1300.	1.4	0
141	Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL.. Blood, 2012, 120, 2563-2563.	1.4	0
142	Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. Blood, 2012, 120, 776-776.	1.4	0
143	Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. Blood, 2012, 120, 1352-1352.	1.4	1
144	BCL6 Interacting Corepressor (BCOR) Functions As Lineage-Specific Tumor Suppressor in B Lymphoid and Myeloid Leukemia. Blood, 2012, 120, 1301-1301.	1.4	2

#	ARTICLE	IF	CITATIONS
145	ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL. <i>Blood</i> , 2012, 120, 291-291.	1.4	5
146	BCOR Is Involved in Myeloid Cell Growth Control by Regulating Hox Genes. <i>Blood</i> , 2012, 120, 3445-3445.	1.4	1
147	Lineage-Specific Functions of LKB1 in CML and B Lymphoid Blast Crisis. <i>Blood</i> , 2012, 120, 34-34.	1.4	0
148	Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 2565-2565.	1.4	0
149	Identification of FoxM1 As Therapeutic Target in TKI-Resistant Ph+ ALL. <i>Blood</i> , 2012, 120, 874-874.	1.4	0
150	Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL. <i>Blood</i> , 2012, 120, 528-528.	1.4	17
151	Cooperation Between Aid and the Rag1/Rag2 V(D)J Recombinase Drives Clonal Evolution of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 519-519.	1.4	2
152	Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 2191-2199.	1.4	102
153	BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. <i>Nature</i> , 2011, 473, 384-388.	27.8	174
154	Global Phosphoproteomics Reveals Crosstalk Between Bcr-Abl and Negative Feedback Mechanisms Controlling Src Signaling. <i>Science Signaling</i> , 2011, 4, ra18.	3.6	56
155	DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival. <i>Blood</i> , 2011, 118, 1479-1479.	1.4	1
156	BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 446-446.	1.4	4
157	Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias. <i>Blood</i> , 2011, 118, 1382-1382.	1.4	0
158	Infectious Origins of Childhood Leukemia. <i>Blood</i> , 2011, 118, 751-751.	1.4	0
159	Mechanisms of Ikaros-Mediated Tumor Suppression. <i>Blood</i> , 2011, 118, 408-408.	1.4	1
160	Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. <i>Blood</i> , 2011, 118, 1406-1406.	1.4	0
161	BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 562-562.	1.4	0
162	Compensatory Signaling From ROR1 and the Pre-B Cell Receptor Promote Survival of t(1;19) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 2466-2466.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Targeting Survivin with YM155 As a Potential Therapy in Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 2490-2490.	1.4	0
164	BCL6 is critical for the development of a diverse primary B cell repertoire. <i>Journal of Experimental Medicine</i> , 2010, 207, 1209-1221.	8.5	108
165	BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 202-202.	1.4	1
166	IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell Receptor. <i>Blood</i> , 2010, 116, 146-146.	1.4	0
167	The Tumor Suppressor PTEN Is Required to Prevent Cellular Senescence and Cell Cycle Arrest In B Cell Lineage and Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 513-513.	1.4	2
168	IL7R α Signaling Prevents Premature Expression of AID In Human Pre-B Cells: Implications for Clonal Evolution of Childhood Leukemia. <i>Blood</i> , 2010, 116, 26-26.	1.4	7
169	Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 274-274.	1.4	1
170	SYK Is a Tumor Suppressor In Pre-B Cell Acute Lymphoblastic Leukemia and Not a Therapeutic Target. <i>Blood</i> , 2010, 116, 4199-4199.	1.4	0
171	Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 147-147.	1.4	1
172	Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires <i>IKAROS</i> function. <i>Journal of Experimental Medicine</i> , 2009, 206, 1739-1753.	8.5	120
173	The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia. <i>Cancer Cell</i> , 2009, 16, 232-245.	16.8	140
174	Human Chromosomal Translocations at CpG Sites and a Theoretical Basis for Their Lineage and Stage Specificity. <i>Cell</i> , 2008, 135, 1130-1142.	28.9	207
175	Conventional Light Chains Inhibit the Autonomous Signaling Capacity of the B Cell Receptor. <i>Immunity</i> , 2007, 26, 323-333.	14.3	74
176	Tracing the Pre-B to Immature B Cell Transition in Human Leukemia Cells Reveals a Coordinated Sequence of Primary and Secondary IGH Gene Rearrangement, IGHK Deletion, and IGL Gene Rearrangement. <i>Journal of Immunology</i> , 2005, 174, 367-375.	0.8	40
177	Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 1837-1852.	8.5	70
178	Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 13266-13271.	7.1	51